Neos Therapeutics (NASDAQ:NEOS) has been given a $20.00 price objective by equities research analysts at Cantor Fitzgerald in a report released on Monday, January 8th. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 92.68% from the stock’s current price.
A number of other research analysts have also recently issued reports on NEOS. Zacks Investment Research cut Neos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 12th. Wells Fargo & Co set a $14.00 price target on Neos Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 18th. Cowen reaffirmed a “buy” rating on shares of Neos Therapeutics in a report on Thursday, October 26th. Finally, BidaskClub raised Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $14.00.
Shares of Neos Therapeutics (NASDAQ NEOS) traded down $0.02 during mid-day trading on Monday, reaching $10.38. The company’s stock had a trading volume of 203,600 shares, compared to its average volume of 310,078. Neos Therapeutics has a one year low of $4.85 and a one year high of $13.15. The company has a debt-to-equity ratio of 4.01, a quick ratio of 2.14 and a current ratio of 2.42. The firm has a market capitalization of $300.84 and a P/E ratio of -3.04.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Neos Therapeutics by 25.7% during the 2nd quarter. Vanguard Group Inc. now owns 740,160 shares of the company’s stock worth $5,403,000 after acquiring an additional 151,166 shares during the last quarter. Cortina Asset Management LLC acquired a new stake in Neos Therapeutics in the third quarter valued at approximately $5,312,000. Stonepine Capital Management LLC acquired a new stake in Neos Therapeutics in the second quarter valued at approximately $4,125,000. State Street Corp grew its stake in Neos Therapeutics by 29.6% in the second quarter. State Street Corp now owns 316,855 shares of the company’s stock valued at $2,312,000 after acquiring an additional 72,395 shares during the period. Finally, Essex Investment Management Co. LLC grew its stake in Neos Therapeutics by 24.2% in the third quarter. Essex Investment Management Co. LLC now owns 238,152 shares of the company’s stock valued at $2,179,000 after acquiring an additional 46,423 shares during the period. Hedge funds and other institutional investors own 45.75% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/neos-therapeutics-neos-given-a-20-00-price-target-at-cantor-fitzgerald/1821118.html.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with our FREE daily email newsletter.